BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 18945538)

  • 1. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Kruck S; Sievert KD
    Eur Urol; 2009 Nov; 56(5):845-6. PubMed ID: 18945542
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L
    Eur Urol; 2009 Nov; 56(5):846-7. PubMed ID: 18945536
    [No Abstract]   [Full Text] [Related]  

  • 4. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival.
    Wülfing C; Eltze E; Yamini J; Wülfing P; Bierer S; Böcker W; Hertle L; Semjonow A; Sievert KD
    Eur Urol; 2005 May; 47(5):593-600. PubMed ID: 15826749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
    Palou J; Algaba F; Vera I; Rodriguez O; Villavicencio H; Sanchez-Carbayo M
    Eur Urol; 2009 Nov; 56(5):829-36. PubMed ID: 18926620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
    Kamai T; Takagi K; Asami H; Ito Y; Oshima H; Yoshida KI
    Br J Cancer; 2001 May; 84(9):1242-51. PubMed ID: 11336477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
    Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
    Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
    van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
    J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up.
    Wülfing P; Diallo R; Kersting C; Wülfing C; Poremba C; Rody A; Greb RR; Böcker W; Kiesel L
    Clin Cancer Res; 2003 Sep; 9(11):4125-31. PubMed ID: 14519635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
    Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
    J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and prognostic relevance of endothelin-B receptor in vulvar cancer.
    Eltze E; Bertolin M; Korsching E; Wülfing P; Maggino T; Lellé R
    Oncol Rep; 2007 Aug; 18(2):305-11. PubMed ID: 17611649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
    Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.